Infective endocarditis by HACEK: a review

Mansoor Khaledi, Fatemeh Sameni, Hamed Afkhami, Jaber Hemmati, Aram Asareh Zadegan Dezfuli, Mohammad-Javad Sanae and Majid Validi

Abstract

Infective endocarditis (IE) is a severe disease that is still associated with high mortality despite recent advances in diagnosis and treatment. HACEK organisms (Haemophilus spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae) are gram-negative bacteria that are part of the normal flora of the mouth and upper respiratory tract in humans. These organisms cause a wide range of infections, of which IE is one of the most notable. In order to control and prevent endocarditis caused by HACEK, measures such as oral hygiene and the use of prophylactic drugs should be used for people at risk, including people with underlying heart disease and people with artificial valves. This review is a summary of the main aspects of IE focusing on HACEK organisms.

Keywords: Endocarditis, Congenital heart disease, HACEK, Echocardiography

Background

Infective endocarditis (IE) is caused by infection of the heart valve blood by fungi and bacteria (this bacteremia can cause septic symptoms) and their vegetative growth, which consists mainly of platelets, microorganisms and fibrins. The superficial growth can cause embolism in many organs such as the kidneys, lungs, skin, brain, and central nervous system, leading to signs of divergence. If the patient with infective endocarditis does not receive adequate treatment, the disease can be lethal [1]. Diagnosis of IE is still difficult, although blood culturing methods, accurate diagnostic criteria and echocardiography have improved [2, 3]. Clinician may also notice possible illnesses such as stroke, heart failure, pulmonary embolism, meningitis, nephritis, collagenosis, pneumonia, or urinary tract infections due to the variety of symptoms in this disease [1].

Main text

Epidemiology

Recently, there have been significant changes in the epidemiology of IE based on the pathogens involved in the disease [4]. Infectious endocarditis is a rare disease with an annual incidence of 3 to 10 cases per 100,000 people [5]. The disease is reported to be twice as common in men as in women. Today, the average age of patients with infective endocarditis is over 65 years, which is probably due to the increasing prevalence of predisposing factors such as artificial valves, acquired valve disease, diabetes mellitus and hemodialysis in this group of people [6].

IE mortality has varied between 13 and 25% and it has been observed that 9–20% of most patients die within the first year after discharge [7]. IE mortality rate in Africa is reported to be more than 26% [8]. In developed countries, the annual prevalence of IE is estimated at 3–9 patients per 100,000 people, an increase that has been seen since 1970–2013 [9]. Despite improvements in patients' prevention and surgery methods, improved antibiotic therapy, and widespread advances in imaging technology, the mortality rate is now high [10]. In developed countries, the epidemiology of IE has changed dramatically, with the number of IE patients as well as the rate of PVE gradually increasing over the last two
decades, with staphylococci being the most significant pathogen involved in IE [11]. The prevalence of IE in Germany between 2005 until 2015 was 11.6 per 100,000 people, which has increased over the years under study [12].

The epidemiology of the disease varied in developing countries, with streptococci being the most significant pathogens involved. Rheumatic heart disease (RHD) and Congenital Heart Disease (CHD) being the most common underlying heart disease, and the number of patients receiving surgical treatment increasing [13, 14].

**IE In children**

Infectious endocarditis is a life-threatening disease in children’s communities. The disease is associated with high mortality [15]. According to some studies, the prevalence of infectious endocarditis in children was lower than in adults, and the rate of hospitalization in children was lower. The prevalence of infective endocarditis is higher in children with CHD and underlying rheumatic disease [16].

Approximately 35–60% of IE infections have CHD, which is a risk factor for IE in children. Congenital heart disease is one of the most common causes of IE in high-income countries. The clinical features of the disease in children vary, which can include weight loss, fever, heart damage, or septic embolization [17, 18].

Recently, an increase in IE cases in children has been reported, which has been observed in these patients with structural heart problems, especially after surgical repair of lesions. More than half of children with IE have children with CHD who have a history of heart surgery. The use of a central venous catheter increases the risk of IE even in children without CHD. It should be noted, however, that a study reported that more than 10% of IE children had no history of any risk factors for the disease, including CHD [19].

The most common IE pathogens in children are gram-positive cocci, especially virulence group α-hemolytic streptococci, staphylococci and enterococci. The HACEK group is one of the rare causes of IE, which accounts for 1.4% of endocarditis cases [20].

The prevalence of infectious endocarditis in children between 1972 and 1982 was 0.75 per 1000 hospitalized [16]. It is noteworthy that between 2003 and 2010, the admission rate of infectious endocarditis per 1000 patients was reported between 0.05 and 0.12 [20, 21].

The annual prevalence of IE is reported to be 0.05–0.12 cases per 1000 hospitalized children and the resulting mortality rate is about 5% [22, 23]. According to studies, the annual prevalence of IE in children in the USA was between 0.34 and 0.64 cases per 100,000 people and approximately 0.05–0.12 people per 1000 children are hospitalized [19].

**Molecular genetic methods and histology in valvular culture**

Examination of the heart valve is the gold standard for diagnosing the IE [1, 3, 24]. If positive, we can identify pathogens in biopsy of the valves from an IE patient by using culture including Gram stain [25]. Histological methods include histochemistry [26] or molecular genetic methods such as PCR [27–29] (Fig. 1). Due to the high concentration of microorganisms in plants, these methods can be used and most of them can be successfully identified [1] by the ways, valvular culture has low negative predictive value for detecting the microorganisms (56%) [28] because of its low sensitivity (15%) [30], (13%) [28], and it is not high specified [31]. However, due to the contamination of the heart valve, we may also see a false positive result in the sample cut from the heart valve during surgery [31]. Sometimes microorganisms detected by methods such as histopathology or PCR from the heart valve may remain there for months after the IE patient has recovered; Therefore, in addition to the experimental methods used, we must ensure the clinical diagnosis of the presence or absence of IE in the patient [25, 32–34].

**Echocardiography**

Echocardiography is a non-surgical test that can show moving images of a patient’s heart with the help of sound waves. The displayed images include the size, shape and quality of how heart valves and chambers working. Echo can detect possible blood clots inside the heart, problems with the aorta and the fluid buildup in the pericardium (the sac around the heart). It is also used to detect heart problems in infants and children [35].

Transthoracic echocardiography (TTE) based on sound transmission through the thoracic wall may allow visualization of vegetations and heart function. The subsequent development of transesophageal echocardiography (TEE) with the sound-emitting probe in the esophagus closer to the heart improved such transmissions substantially. With its higher sensitivity TEE detects small vegetations, infection of prosthetic heart valves, infected pacemaker leads and perivalvular abscesses. However, TTE has improved with the second harmonic imaging [1, 36–38].

**Infective Endocarditis caused by hACEK microorganisms**

**Endocarditis caused by HACEK organisms**

HACEK endocarditis mostly affects most patients with heart disease or artificial valves, and is characterized by an insidious course, with a mean diagnosis delay of 1 month (Haemophilus spp.) to 3 months (Aggregatibacter and Cardiobacterium spp.) [39]. In Olmsted County, Minnesota, about 0.14 of every 100,000 people develop
HACEK endocarditis each year. 12 cases occurred in patients with prosthetic valve, and in patients with native valve, 33 cases occurred [40].

The HACEK group of bacteria—Haemophilus parainfluenzae, Aggregatibacter spp. (A. actinomycetemcomitans, A. aphrophilus, A. paraphrophilus, and A. segnis), Cardiobacterium hominis and valvarum, Eikenella corrodens, Kingella kingae and denitrificans—are fastidious gram-negative bacteria, part of the normal microbiota of oral and upper respiratory tract in humans. Although their pathogenicity is low, they are responsible for 1–3% of infectious endocarditis [39].

Bacteria of the HACEK group are grouped together in infectious endocarditis due to similar characteristics such as: presence in the pharyngeal microbiota, low virulence, similar infections and most importantly (IE) [41]. Hard-growing Gram-negative organisms of primary oral origin are the main cause of infectious endocarditis [39]. Common features of HACEK microorganisms are that they grow slowly and often colonize the oropharynx, and if we add CO2 in their medium culture, their growth will be enhanced [40].

HACEK microorganisms cause disease such as periodontal infections, bacteremia, endocarditis, and polymicrobial wound infections [36] otitis media, and abscesses [36, 42, 43]. Native-valve or prosthetic-valve endocarditis caused by HACEK microorganisms is associated with a favorable prognosis [44, 45].

Cases of endocarditis caused by HACEK microorganisms were studied, the etiologic agent for Actinobacillus...
actinomycetemcomitans was 9 patients (20%). The etiologic agents for other microorganisms of the HACEK group were as follows: Eickenella corrodens, 2 patients (4%); Haemophilus aphrophilus, 7 patients (16%); Haemophilus parainfluenzae, 12 patients (27%) Cardiobacterium hominis, 12 patients (27%); and Kingella kingii, 3 patients (7%) [40]. This study shows the highest and lowest causes of endocarditis, respectively is Actinobacillus actinomycetemcomitans and Eickenella corrodens.

The demographic data on patients with HACEK endocarditis the most prevalent agents were Haemophilus parainfluenzae, Haemophilus aphrophilus, and Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eickenella corrodens, and Kingella kingii, respectively) shows that most patients, presented with fever, and most patients presented with splenomegaly, new or altered murmurs, and micro embolic or immunologic phenomena. Approximately half of the patients had heart disease, including bicuspid aortic valve, coarctation of the aorta with aortic insufficiency associated with Marfans syndrome, mitral valve prolapse, atrial and ventricular septal defects, or valvular heart disease associated with preexisting rheumatic fever [40].

The pathogenesis of HACEK endocarditis is thought to be due to colonization of the oropharynx with bacteria that reach the vascular space following either trauma or local infection [46–49].

The most positive predictive value (PPV) of bacteremia for endocarditis varied with HACEK species, ranging from 100% for A. actinomycetemcomitans to 0% for E. corrodens. A. actinomycetemcomitans in blood cultures is always associated with endocarditis [50] and there is just a low percentage sometimes shows pneumonia or periaortic osteoradionecrosis in the setting of nasopharyngeal carcinoma [50, 51].

Actinobacillus actinomycetemcomitans, is a part of the natural flora of the mouth and it is often found in human periodontal culture, it is an important pathogen that causes a variety of invasive infections, especially infective endocarditis [51].

A number of patients with invasive infections due to A. actinomycetemcomitans, had about 50% previously reported cases, that most of them had A. actinomycetemcomitans endocarditis, and there were very few with osteonecrosis, and pneumonia and chest wall mass lesion [51–53].

Results of the proposed pathogenesis studies of HACEK endocarditis

1. The microorganisms are located in the oropharynx [40, 54] and enter the vascular chamber at the time of dental work or in the context of periodontal disease [55–57], almost half of the patients had either weak teeth or recent dental work within the study [40].
2. The microorganisms are generally considered to be of low virulence and infect structurally damaged or prosthetic cardiac valves, they mostly occur in patients that have preexisting structural cardiac disease, also there is a medium amount in patients with prosthetic valves [40].
3. These microorganisms are fastidious and slow growing, also they may cause infection for a prolonged period prior to diagnosis [27, 40, 54, 58].
4. Various studies have shown that these microorganisms have low growth or no growth in blood culture and this may lead to delay in microbiological diagnosis in patients with negative blood culture. HACEK should be considered in the differential diagnosis of negative endocarditis culture [40, 45].
5. These microorganisms have historically been susceptible to β-lactam antimicrobials [59] despite reports of beta-lactamase production [60].
6. The diagnosis of HACEK endocarditis of either native or prosthetic valves is associated with a good prognosis [44, 45].

Diagnostic measures

The HACEK group are known as blood culture-negative organisms but if organisms are exposed to carbon dioxide or enriched blood culture medium, they are more easily identified [40, 61, 62]. Better results on grow of these microorganisms is by subculture in 5% sheep blood and chocolate agar at 37° C under 5–10% CO2 [27, 63]. In addition, the use of BacT/Alert system in the first 5 days of blood culture is 99% sensitive in identifying the organism [64]. According to the European IE Guidelines for 2009, long-term incubation is recommended only if IE detection of negative cultures after 72.Hr [65]. prolonged incubation has no value in diagnosing culture negative endocarditis [66]. Contrary to previous notions about culturing HACEK organisms, which are very difficult, experience has shown that this group separates after an average incubation period of 3 days, with an average of 4.3 days when using automated blood culture systems [62, 67]. Additionally, it is not true that longer incubation is more effective in the growth of HACEK organisms [68]. American Heart Association (AHA) asserts that Initially negative cultures are involved in all patients with suspected IE for more than 2 weeks [69]. Recently, Laser ionization by matrix-time flight mass spectrometry (MALDI-TOF MS) has been very successful in identifying highly sensitive HACEK organisms. It has also been shown that MALDITOF MS allows the earlier identification of species belonging to the HACEK group. [70].
When the HACEK organism grows on a blood culture (under the conditions above), gradient tests, such as E-test (strip impregnated with antimicrobials), are used to determine the susceptibility of the organism to different antibiotics [71].

Treatments
Delay in diagnosis and its complications can be fatal for humans. Ampicillin in combination with gentamicin [62] is standard treatment for 4 weeks for normal valve infection and for 6 weeks for synthetic valve infection. Surgical procedures follow the recommendations of the Endocarditis Working Group of the International Society of Chemotherapy [72].

The guidelines recommend that ampicillin-resistant organisms be considered because of the difficulty in detecting susceptibility and the potential for resistance among HACEK microorganisms. Therefore, broad-spectrum cephalosporins or fluoroquinolones are considered the first line of treatment for HE (HACEK endocarditis) [73, 74].

Ampicillin should not be prescribed to patients with HE unless the organism is found to be sensitive, and gentamicin is no longer recommended due to its nephrotoxic risks [62, 69]. The standard treatment for HE is intravenous ceftriaxone monotherapy with 2 g per day. The diet should be given for 4 weeks in NVE (native valve endocarditis) and for 6 weeks in prosthetic valve endocarditis [69, 73]. Alternative, rarely used options in cases of β-lactam allergy include fluoroquinolones such as levofloxacin, ciprofloxacin or moxifloxacin [73, 74].

One of the benefits of surgical intervention is valve tissue resection, which can be used for microbiological documentation [58]. However, surgical intervention is necessary in case of heart failure, paravular proliferation, persistence of infection despite appropriate antimicrobial treatment and/or prevention of embolism. These indications for surgery apply to native, as well as prosthetic, valve HE [73, 75]. After surgical treatment, if tissue cultures are negative, antibiotic treatment should be continued to complete the preoperative period, starting with the first negative blood culture after diagnosis of HE. In case of positive tissue cultures, a full course of antibiotics should be started from the time of surgery according to the sensitivity characteristics of the operated cultures [69, 75].

A recently published study by Lee et al. illuminated that surgical mitral valve repair with lifting annuloplasty strip for patients with acute phase infective endocarditis, including HE, which sometimes has a 5-year survival. This study also showed a significant decrease in left ventricular diastolic end dimensions with no/minimal regurgitation up to a median follow-up of 54 months post operation [76]. In the past, prevention before invasive dental procedures was a model recommendation for the prevention of bacterial endocarditis of oral and pharyngeal organisms, especially HACEK organisms and streptococci of the viridans group. The recommendation was overturned by the AHA in 2007 after population-based data showed that only a few cases of IE could be prevented by prescribing prophylactic antibiotics for dental procedures [77, 78].

Prevention and prophylaxis
Recently, prophylaxis attributable to invasive dental operations was a normal precaution for the prevention of infections endocarditis from oropharyngeal bacteria especially HACEK and viridians streptococci group. However, this suggestion was withdrawn by AHA in 2007, after population-based evidence showed that only a minimal percentage of IE cases are eliminated by the use of antibiotic prophylaxis for dental procedures [77]. Scientific studies and growing evidence continue to contradict and refine the suggested prophylactic techniques. Antibacterial prophylaxis is now approved for use in particular high-risk cases, such as the involvement of a prosthetic heart valve, prior history of IE, uncorrected or newly corrected CHD, and the occurrence of prosthetic heart valve disorders [73]. For patients in these high-risk groups, prophylaxis is recommended prior to dental operations involving stimulation of the gingival tissue or For patients in these high-risk groups, prophylaxis is recommended prior to dental operations involving stimulation of the gingival tissue or periapical area of the teeth or destruction of oral mucosa such as root canal processes [77]. Antibiotic prophylaxis is not approved for using local anesthetic of non—infected areas, for the prevention of superficial caries, for the insertion of sutures, dental x-rays, for the positioning or modification of removable implantation of prosthesis or orthodontics, or for damage to the lips and mucous membranes [73].

The key focus for antibiotic prophylaxis in these groups is oral streptococci, although HACEK group are also considered. The most prescribed prophylaxis are amoxicillin or ampicillin, 2 g orally or intravenously in adults and 50 mg/kg orally or intravenously in non-adults, according to the ESC 2015 standards. In the penicillin or ampicillin allergy, clindamycin can be chosen to give at 600 mg for adults and 20 mg/kg in in non-adults. The antibiotics are supplied as a single dose 30–60 min prior to the dental procedure [73]. However, while antibacterial prophylaxis is limited to high-risk populations, such prevention steps should be extended to all cardiac disease. The ESC Standards recommend non-specific preventive steps, such as stringent oral and skin care, 2-yearly dental follow-up, wound disinfection, therapeutic antibiotics for bacterial
infection, no antibiotic self-medication and minimal use of catheters and aggressive methods [73].

Conclusion
The epidemiology and management of infectious endocarditis treatment is constantly changing and these statistics have been reported in different countries. The guidelines provide specific recommendations for the management of infectious endocarditis. However, when making decisions about infectious endocarditis treatment, care must be taken with the individual characteristics of the patient, the type of pathogen, and the risk of disease consequences in different population and age groups.

Abbreviations
IE: Infective endocarditis; RHD: Rheumatic heart disease; CHD: Coronary heart disease; HACEK: Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella; TTE: Transthoracic echocardiography; TEE: Transesophageal echocardiography; PPV: Positive predictive value; AHA: American heart association; MALDI-TOF MS: Laser ionization by matrix-time flight mass spectrometry.

Acknowledgements
Not applicable.

Author contributions
The authors have declared that no competing interests exist.

Competing interests
The authors have declared that no competing interests exist.

Acknowledgements
Not applicable.

Availability of data and materials
Any additional information can be obtained from the corresponding author on request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interests exist.

Author details
1Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran. 2Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. 3Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Received: 9 September 2021 Accepted: 13 August 2022 Published online: 19 August 2022

References
1. Werner M, Andersson R, Olason L, Hogevik H. Endocarditis SSIDQASGF. A 10-year survey of blood culture negative endocarditis in Sweden: aminoglycoside therapy is important for survival. Scand J Infect Dis. 2008;40(4):275–85.
2. Habib G, Deremaux G, Avierinos J-F, Casalta J-P, Jamal F, Volot F, et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol. 1999;33(7):2023–9.
3. Von Reyn CF, LEVY BS, ARBEIT RD, FRIELAND G, CRUMPACKER CJS. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med. 1981;94(4_Part_1):505–18.
4. Talha KM, DeSimone DC, Sohal MR, Baddour LM. Pathogen influence on epidemiology, diagnostic evaluation and management of infective endocarditis. Heart. 2020;106(24):1878–82.
5. Yallowitz AW, Decker LC. Infectious endocarditis. StatPearls [Internet]. 2020.
6. de Sa DDC, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, et al., editors. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clinic Proceedings; 2010. Elsevier.
7. Muhoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodríguez-Abella H, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine. 2015;94(43):e1816.
8. Yameogo N, Kologo K, Yameogo A, Yonaba C, Willogo G, Kissou S, et al., editors. Infective endocarditis in sub-Saharan African children, cross-sectional study about 19 cases in Ouagadougou at Burkina Faso. Annales de Cardiologie et D‘Angéiologie, 2013.
9. Wu Z, Chen Y, Xiao T, Niu T, Shi Q, Xiao Y. Epidemiology and risk factors of infective endocarditis in a tertiary hospital in China from 2007 to 2016. BMC Infect Dis. 2020;20(1):1–10.
10. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017;69(3):325–44.
11. Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericás J, Falces C, Toslosana J, et al. The changing epidemiology of infective endocarditis in the twenty-first century. Curr Infect Dis Rep. 2017;19(5):21.
12. Keller K, von Bardeleben RS, Ostad MA, Hobbolt L, Munzel T, Konstantinides S, et al. Temporal trends in the prevalence of infective endocarditis in Germany between 2005 and 2014. Am J Cardiol. 2017;119(2):317–22.
13. Elbey MA, Akdağ S, Kalkan ME, Kaya MG, Sayin MR, Karapinar H, et al. A multicenter study on experience of 13 tertiary hospitals in Turkey in patients with infective endocarditis. Anadolu Kardiyol Derg. 2013;13(6):523–7.
14. Njugu N, Gardner A, Karwa R, Delahaye F. Infective endocarditis in low- and middle-income countries. Cardiol Clin. 2017;35(3):153–63.
15. Moges T, Gedlu E, Isaakidis P, Kumar A, Van Den Berge R, Khogali M, et al. Infective endocarditis in Ethiopian children: a hospital based review of cases in Addis Ababa. Pan Afr Med J. 2015;20:75.
16. Awadallah SH, Kavey R-EW, Byrum CJ, Smith FC, Kveselis DA, Blackman MS. The changing pattern of infective endocarditis in childhood. The American journal of cardiology. 1991;68(1):90–4.
17. Lin YT, Hsieh KH, Chen Y-S, Huang I-F, Cheng M-F. Infective endocarditis in children without underlying heart disease. J Microbiol Immunol Infect. 2015;48(3):211–8.
18.avs S, et al. Temporal trends in the prevalence of infective endocarditis in children in Addis Ababa. Pan Afr Med J. 2015;20:75.
19. eda S, et al. Temporal trends in the prevalence of infective endocarditis in children in Addis Ababa. Pan Afr Med J. 2015;20:75.
20. eda S, et al. Temporal trends in the prevalence of infective endocarditis in children in Addis Ababa. Pan Afr Med J. 2015;20:75.
24. Durack DT, Lukes AS, Bright DK, Service DE. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994;96(3):200–9.

25. Morris AJ, Drnkovic D, Pottummarthy S, Stickett MG, MacCulloch D, Lumbie N, et al. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. Clin Infect Dis. 2003;36(6):697–704.

26. Lepidi H, Coulibaly B, Casalta J-P, Raoult D. Autoimmunohistochemistry: a new method for the histologic diagnosis of infective endocarditis. J Infect Dis. 2006;193(12):1711–7.

27. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clinical Microbiol Rev. 2001;14(1):177–207.

28. Greub G, Lepidi H, Rovery C, Casalta J-P, Habib G, Collard F, et al. Diagnosis of infectious endocarditis in patients undergoing valve surgery. Am J Med. 2005;118(3):230–8.

29. Breitkopf C, Hammel D, Scheld HH, Peters G, Becker K. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. Circulation. 2005;111(11):1415–21.

30. Renzulli A, Carozza A, Romano G, De Feo M, Della Corte A, Gregorio R, et al. Recurrent infective endocarditis: a multivariate analysis of 21 years of experience. Ann Thorac Surg. 2001;72(1):39–43.

31. Giladi M, Szold O, Elami A, Bruckner D, Johnson B Jr. Microbiological cultures of heart valves and valve tags are not valuable for patients without infective endocarditis who are undergoing valve replacement. Clin Infect Dis. 1997;24(5):884–8.

32. Rovery C, Greub G, Lepidi H, Casalta J-P, Habib G, Collard F, et al. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. J Clin Microbiol. 2005;43(1):163–7.

33. Lang S, Watkin R, Lambert P, Littler W, Elliott T. Detection of bacterial DNA in cardiac vegetations by PCR after the completion of antimicrobial treatment for endocarditis. Clin Microbiol Infect. 2004;10(6):579–81.

34. Lang S, Watkin R, Lambert P, Bonser R, Littler W, Elliott T. Evaluation of PCR in the molecular diagnosis of endocarditis. J Infect. 2004;48(3):269–75.

35. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Polidermans D, et al. Stress echocardiography expert consensus statement: European association of echocardiography (EAE) a registered branch of the ESC. Eur J Echocardiogr. 2008;9(4):415–37.

36. Chirillo F, Pedracco A, De Leo A, Bruni A, Totis O, Meneghetti P, et al. Impact of harmonic imaging on transthoracic echocardiographic identification of infective endocarditis and its complications. Heart. 2005;91(3):329–33.

37. Evangelista A, Gonzalez-Alujas M. Echocardiography in infective endocarditis. Expert Rev Anti Infect Ther. 2003;1(4):523–30.

38. Chirillo F, Pedracco A, De Leo A, Bruni A, Totis O, Meneghetti P, et al. Impact of harmonic imaging on transthoracic echocardiographic identification of infective endocarditis and its complications. Heart. 2005;91(3):329–33.

39. Chen P-C, Tung Y-C, Wu PW, Wu L-S, Lin Y-S, Chang C-J, et al. Prevalence and the risk of infective endocarditis. Medicine. 2015;94(39):e1826.

40. Barone EJ, Scott JD, Tomskins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically important microorganisms from standard automated blood cultures. Clin Infect Dis. 2005;41(11):1677–80.

41. Reyes MP, Reyes KC. Gram-negative endocarditis. Curr Infect Dis Rep. 2008;10(4):267–74.

42. Dall L, Barnes W, Gibbs H, Nohinek B, Zee-Cheng C. Endocarditis caused by beta-lactamase-producing Haemophilus influenzae. South Med J. 1987;80(3):405–6.

43. Koneman EW, Allen SD, Janda W, Gerding DN. Favorable prognosis of patients with prosthetic valve endocarditis caused by beta-lactamase-producing Haemophilus influenzae. South Med J. 1987;80(3):405–6.

44. Meyer DJ, Gerding DN. Cardiobacterium hominis endocarditis: a case report and review of the literature. Clin Infect Dis. 2005;41(11):1677–80.

45. Goultzmanis J, Gonis G, Gilbert G. Inequality of children in infections: ten cases adn a review of the literature. Pediatr Infect Dis J. 1999;18(10):677–83.

46. Chen P-C, Tung Y-C, Wu PW, Wu L-S, Lin Y-S, Chang C-J, et al. Dental procedures and the risk of infective endocarditis. Medicine. 2015;94(39):e1826.

47. Koegelenberg C, Doubell A, Orth H, Reuter H. Infective endocarditis in the western cape province of South Africa: a three-year prospective study. QJM. 2003;96(3):217–25.
70. Couturier MR, Mehinovic E, Croft AC, Fisher MA. Identification of HACEK clinical isolates by matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol. 2011;49(3):1104–6.
71. Gould FK, Denning DW, Elliott TS, Fowler J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the british society for antimicrobial chemotherapy. J Antimicrob Chemother. 2012;67(2):269–89.
72. Pettersson G, Carbon C. Recommendations for the surgical treatment of endocarditis. Clin Microbiol Infect. 1998;4:3534–46.
73. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (ESC) endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur Heart J. 2015;36(44):3075–128.
74. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86.
75. Nishimura R, Otto C, Bonow R, Carabello B, Erwin J, Guyton R, et al. Correction: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines. (journal of the American college of cardiology (2014) 63 (2438-88)). J Am Coll Cardiol. 2014;63(22):e57–185.
76. Lee SJ, Yang HS, Kim JS, Shin JK, Son JS, Song MG, et al. Midterm results of mitral valve repair with lifting annuloplasty strip for acute phase infective endocarditis. J Cardiothorac Surg. 2015;10(1):1–7.
77. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American heart association: a guideline from the American heart association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116(15):1736–54.
78. Van der Meer J, Michel M, Valkenburg H, van Wijk W, Thompson J, Vandebrooke J. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet. 1992;339(8786):135–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.